臨床婦人科産科72巻6号

2018年06月発行

今月の臨床 がん免疫療法の新展開─「知らない」ではすまない今のトレンド がん免疫療法の分類と作用機序

腫瘍免疫の新しい理解と免疫療法のターゲット

著者： 田中淳¹ 坂口志文¹

所属機関： ¹大阪大学免疫学フロンティア研究センター・実験免疫学

ページ範囲：P.524 - P.529

●制御性T細胞は，多様ながん種の腫瘍局所に浸潤し，予後不良との相関が高い．

●制御性T細胞は，腫瘍抗原に対する免疫応答を抑制することから，腫瘍に浸潤する制御性T細胞の除去は，抗腫瘍免疫応答を賦活化する．

●腫瘍浸潤制御性T細胞の除去による免疫抑制解除と，がんワクチンや抗体療法によるCD8^＋T細胞の賦活化を組み合わせることで，効果的ながん免疫療法が期待される．

参考文献

1）Tanaka A, et al : Regulatory T cells in cancer immunotherapy. Cell Res 27 : 109─118, 2017

2）Sakaguchi S, et al : Regulatory T cells and immune tolerance. Cell 133 : 775─787, 2008

regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 : 531─562, 2004

4）Bates GJ, et al : Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24 : 5373─5380, 2006

regulatory T cells in patients with gastrointestinal malignancies : possible involvement of regulatory T cells in disease progression. Cancer 98 : 1089─1099, 2003

6）Curiel TJ, et al : Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 : 942─949, 2004

T cells : a common basis between tumor immunity and autoimmunity. J Immunol 163 : 5211─5218, 1999

regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 70 : 7788─7799, 2010

9）Yamaguchi T, et al : Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression. Proc Natl Acad Sci U S A 110 : E2116─E2125, 2013

regulatory T cell function. Science 322 : 271─275, 2008

11）Miyara M, et al : Functional delineation and differentiation dynamics of human CD4＋T cells expressing the FoxP3 transcription factor. Immunity 30 : 899─911, 2009

regulatory T cells in humans. Proc Natl Acad Sci U S A 112 : 7225─7230, 2015

regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 110 : 17945─17950, 2013

T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med 22 : 679─684, 2016

15）Hodi FS, et al : Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105 : 3005─3010, 2008

cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105 : 14987─14992, 2008

17）Simpson TR, et al : Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210 : 1695─1710, 2013

18）Bulliard Y, et al : Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210 : 1685─1693, 2013

19）Selby MJ, et al : Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1 : 32─42, 2013

20）Taylor NA, et al : Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. J Clin Invest 127 : 3472─3483, 2017

21）Dannull J, et al : Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 : 3623─3633, 2005

22）Attia P, et al : Inability of a fusion protein of IL-2 and diphtheria toxin（Denileukin Diftitox, DAB389IL-2, ONTAK） to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28 : 582─592, 2005

23）Rech AJ, et al : CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 4 : 134ra62, 2012

24）Arce Vargas F, et al : Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46 : 577─586, 2016